To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension
Study identifier:D1020C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter regulatory Response during Hypoglycaemia in Healthy Male Volunteers after a Single Oral Dose of AZD1656 Suspension in Comparison with Insulin Infusion
Medical condition
Type 2 Diabetes
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Insulin, AZD1656
Sex
Male
Actual Enrollment
12
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Nov 2008
Primary Completion Date: -
Study Completion Date: 01 Feb 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 AZD1656 | Drug: AZD1656 Single dose oral suspension given at one occasion. |
| Active Comparator: 2 Insulin | Drug: Insulin Insulin infusion given during 3 hours at one occasion. |
Contacts
Investigators
Principal Investigator
Klas Malmberg
AstraZeneca R&D Mölndal
